Xiaoxi Zheng, Beth Ehrlich, David Finlay, Michelle Glass
{"title":"没有证据表明人类和啮齿类动物的大麻素 CB1 受体具有内源性大麻素诱导的 G 蛋白亚型选择性。","authors":"Xiaoxi Zheng, Beth Ehrlich, David Finlay, Michelle Glass","doi":"10.1089/can.2024.0133","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> The endocannabinoid system (ECS) is a widespread neurotransmitter system. A key characteristic of the ECS is that there are multiple endogenous ligands (endocannabinoids). Of these, the most extensively studied are arachidonoyl ethanolamide (AEA) and 2-arachidonoyl-glycerol (2-AG), both act as agonists at the cannabinoid CB<sub>1</sub> receptor. In humans, three CB<sub>1</sub> variants have been identified: hCB<sub>1</sub>, considered the most abundant G protein-coupled receptor in the brain, alongside the less abundant and studied variants, hCB<sub>1a</sub> and hCB<sub>1b</sub>. CB<sub>1</sub> exhibits a preference for coupling with inhibitory G<sub>i/o</sub> proteins, although its interactions with specific members of the G<sub>i/o</sub> family remain poorly characterized. This study aimed to compare the AEA and 2-AG-induced activation of various G protein subtypes at CB<sub>1</sub>. Furthermore, we compared the response of human CB<sub>1</sub> (hCB<sub>1</sub>, hCB<sub>1a</sub>, hCB<sub>1b</sub>) and explored species differences by examining rodent receptors (mCB<sub>1</sub>, rCB<sub>1</sub>). <b>Materials and Methods:</b> Activation of individual G protein subtypes in HEK293 cells transiently expressing CB<sub>1</sub> was measured with G protein dissociation assay utilizing TRUPATH biosensors. The performance of the TRUPATH biosensors was evaluated using Z-factor analysis. Pathway potencies and efficacies were analyzed using the operational analysis of bias to determine G protein subtype selectivity for AEA and 2-AG. <b>Results:</b> Initial screening of TRUPATH biosensors performance revealed variable sensitivities within our system. Based on the biosensor performance, the G protein subtypes pursued for further characterization were G<sub>i1</sub>, G<sub>i3</sub>, G<sub>oA</sub>, G<sub>oB</sub>, G<sub>Z</sub>, G<sub>12</sub>, and G<sub>13</sub>. Across all pathways, AEA demonstrated partial agonism, whereas 2-AG exhibited full or high-efficacy agonism. Notably, we provide direct evidence that the hCB<sub>1</sub> receptor couples to G<sub>12</sub> and G<sub>13</sub> proteins. Our findings do not indicate any evidence of G protein subtype selectivity. Similar observations were made across the human receptor variants (hCB<sub>1</sub>, hCB<sub>1a</sub>, hCB<sub>1b</sub>), as well as at mCB<sub>1</sub> and rCB<sub>1</sub>. <b>Discussion:</b> There was no evidence suggesting G protein subtype selectivity for AEA and 2-AG at CB<sub>1</sub>, and this finding remained consistent across human receptor variants and different species.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"No Evidence for Endocannabinoid-Induced G Protein Subtype Selectivity at Human and Rodent Cannabinoid CB<sub>1</sub> Receptors.\",\"authors\":\"Xiaoxi Zheng, Beth Ehrlich, David Finlay, Michelle Glass\",\"doi\":\"10.1089/can.2024.0133\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Introduction:</b> The endocannabinoid system (ECS) is a widespread neurotransmitter system. A key characteristic of the ECS is that there are multiple endogenous ligands (endocannabinoids). Of these, the most extensively studied are arachidonoyl ethanolamide (AEA) and 2-arachidonoyl-glycerol (2-AG), both act as agonists at the cannabinoid CB<sub>1</sub> receptor. In humans, three CB<sub>1</sub> variants have been identified: hCB<sub>1</sub>, considered the most abundant G protein-coupled receptor in the brain, alongside the less abundant and studied variants, hCB<sub>1a</sub> and hCB<sub>1b</sub>. CB<sub>1</sub> exhibits a preference for coupling with inhibitory G<sub>i/o</sub> proteins, although its interactions with specific members of the G<sub>i/o</sub> family remain poorly characterized. This study aimed to compare the AEA and 2-AG-induced activation of various G protein subtypes at CB<sub>1</sub>. Furthermore, we compared the response of human CB<sub>1</sub> (hCB<sub>1</sub>, hCB<sub>1a</sub>, hCB<sub>1b</sub>) and explored species differences by examining rodent receptors (mCB<sub>1</sub>, rCB<sub>1</sub>). <b>Materials and Methods:</b> Activation of individual G protein subtypes in HEK293 cells transiently expressing CB<sub>1</sub> was measured with G protein dissociation assay utilizing TRUPATH biosensors. The performance of the TRUPATH biosensors was evaluated using Z-factor analysis. Pathway potencies and efficacies were analyzed using the operational analysis of bias to determine G protein subtype selectivity for AEA and 2-AG. <b>Results:</b> Initial screening of TRUPATH biosensors performance revealed variable sensitivities within our system. Based on the biosensor performance, the G protein subtypes pursued for further characterization were G<sub>i1</sub>, G<sub>i3</sub>, G<sub>oA</sub>, G<sub>oB</sub>, G<sub>Z</sub>, G<sub>12</sub>, and G<sub>13</sub>. Across all pathways, AEA demonstrated partial agonism, whereas 2-AG exhibited full or high-efficacy agonism. Notably, we provide direct evidence that the hCB<sub>1</sub> receptor couples to G<sub>12</sub> and G<sub>13</sub> proteins. Our findings do not indicate any evidence of G protein subtype selectivity. Similar observations were made across the human receptor variants (hCB<sub>1</sub>, hCB<sub>1a</sub>, hCB<sub>1b</sub>), as well as at mCB<sub>1</sub> and rCB<sub>1</sub>. <b>Discussion:</b> There was no evidence suggesting G protein subtype selectivity for AEA and 2-AG at CB<sub>1</sub>, and this finding remained consistent across human receptor variants and different species.</p>\",\"PeriodicalId\":9386,\"journal\":{\"name\":\"Cannabis and Cannabinoid Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-10-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cannabis and Cannabinoid Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/can.2024.0133\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cannabis and Cannabinoid Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/can.2024.0133","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
简介内源性大麻素系统(ECS)是一种广泛存在的神经递质系统。ECS 的一个主要特点是存在多种内源性配体(内源性大麻素)。其中,研究最为广泛的是花生四烯丙基乙醇酰胺(AEA)和 2-花生四烯丙基甘油(2-AG),它们都是大麻素 CB1 受体的激动剂。在人体中,已经发现了三种 CB1 变体:hCB1(被认为是大脑中含量最高的 G 蛋白偶联受体),以及含量较低、研究较少的变体 hCB1a 和 hCB1b。尽管 CB1 与 Gi/o 家族的特定成员之间的相互作用特征尚不十分明确,但它偏好与抑制性 Gi/o 蛋白耦合。本研究旨在比较 AEA 和 2-AG 在 CB1 上诱导激活各种 G 蛋白亚型的情况。此外,我们还比较了人类 CB1(hCB1、hCB1a、hCB1b)的反应,并通过研究啮齿动物受体(mCB1、rCB1)探讨了物种差异。材料和方法:在瞬时表达 CB1 的 HEK293 细胞中,利用 TRUPATH 生物传感器的 G 蛋白解离测定法测量了单个 G 蛋白亚型的激活情况。利用 Z 因子分析评估了 TRUPATH 生物传感器的性能。使用偏差运算分析法分析了通路效力和效率,以确定 G 蛋白亚型对 AEA 和 2-AG 的选择性。结果:对 TRUPATH 生物传感器性能的初步筛选显示,我们的系统具有不同的灵敏度。根据生物传感器的性能,需要进一步鉴定的 G 蛋白亚型包括 Gi1、Gi3、GoA、GoB、GZ、G12 和 G13。在所有途径中,AEA 表现出部分激动作用,而 2-AG 则表现出完全或高效激动作用。值得注意的是,我们提供了 hCB1 受体与 G12 和 G13 蛋白偶联的直接证据。我们的研究结果没有显示任何 G 蛋白亚型选择性的证据。人类受体变体(hCB1、hCB1a、hCB1b)以及 mCB1 和 rCB1 也有类似的观察结果。讨论没有证据表明在 CB1 上 G 蛋白亚型对 AEA 和 2-AG 具有选择性,这一发现在人类受体变体和不同物种之间保持一致。
No Evidence for Endocannabinoid-Induced G Protein Subtype Selectivity at Human and Rodent Cannabinoid CB1 Receptors.
Introduction: The endocannabinoid system (ECS) is a widespread neurotransmitter system. A key characteristic of the ECS is that there are multiple endogenous ligands (endocannabinoids). Of these, the most extensively studied are arachidonoyl ethanolamide (AEA) and 2-arachidonoyl-glycerol (2-AG), both act as agonists at the cannabinoid CB1 receptor. In humans, three CB1 variants have been identified: hCB1, considered the most abundant G protein-coupled receptor in the brain, alongside the less abundant and studied variants, hCB1a and hCB1b. CB1 exhibits a preference for coupling with inhibitory Gi/o proteins, although its interactions with specific members of the Gi/o family remain poorly characterized. This study aimed to compare the AEA and 2-AG-induced activation of various G protein subtypes at CB1. Furthermore, we compared the response of human CB1 (hCB1, hCB1a, hCB1b) and explored species differences by examining rodent receptors (mCB1, rCB1). Materials and Methods: Activation of individual G protein subtypes in HEK293 cells transiently expressing CB1 was measured with G protein dissociation assay utilizing TRUPATH biosensors. The performance of the TRUPATH biosensors was evaluated using Z-factor analysis. Pathway potencies and efficacies were analyzed using the operational analysis of bias to determine G protein subtype selectivity for AEA and 2-AG. Results: Initial screening of TRUPATH biosensors performance revealed variable sensitivities within our system. Based on the biosensor performance, the G protein subtypes pursued for further characterization were Gi1, Gi3, GoA, GoB, GZ, G12, and G13. Across all pathways, AEA demonstrated partial agonism, whereas 2-AG exhibited full or high-efficacy agonism. Notably, we provide direct evidence that the hCB1 receptor couples to G12 and G13 proteins. Our findings do not indicate any evidence of G protein subtype selectivity. Similar observations were made across the human receptor variants (hCB1, hCB1a, hCB1b), as well as at mCB1 and rCB1. Discussion: There was no evidence suggesting G protein subtype selectivity for AEA and 2-AG at CB1, and this finding remained consistent across human receptor variants and different species.